Australia markets open in 8 hours 30 minutes

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
8.52+0.05 (+0.59%)
As of 11:29AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close8.47
Open8.56
Bid8.54 x 4000
Ask8.55 x 1000
Day's range8.42 - 8.64
52-week range7.23 - 11.55
Volume2,024,160
Avg. volume9,208,500
Market cap9.46B
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)-0.56
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est10.17
  • Business Wire

    Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting

    TEL AVIV, Israel & PARSIPPANY, N.J., May 23, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (TD). These data will be presented at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10. In addition, ne

  • Business Wire

    United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

    AMSTERDAM, May 17, 2022--Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia® for the treatment of neovascular (wet) age-related macular degeneration ("AMD"). Ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oedema (DM

  • Business Wire

    Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting

    TEL AVIV, Israel & PARSIPPANY, N.J., May 17, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO® (deutetrabenazine) tablets and TV-46000/mdc-IRM. These data will be presented at the American Psychiatric Association (APA) Annual Meeting held May 21-25, 2022 in New Orleans, Louisiana, and again virtually June 7-10, 2022.